Savolitinib, a potent and selective small-molecule MET kinase inhibitor, was tolerable, safe, and may have treatment potential for patients with MET-driven papillary renal cell carcinoma (PRCC), according to a trial published in the Journal of Clinical Oncology.1
Metastasis, angiogenesis, tumor growth, and treatment resistance are each associated with MET activation and lead to a poor prognosis in many cancers. The primary objective of this study was to determine savolitinib activity in PRCC tumors by MET status.
This single arm, phase 2 study (ClinicalTrial.gov ID: NCT02127710) enrolled 109 patients and assessed the safety and efficacy of savolitinib in patients with histologically confirmed locally advanced or metastatic PRCC. Forty percent of patients had MET-driven PRCC, 42% were MET-independent, and 17% had unknown MET status. Patients received savolitinib 600 mg once daily.
Continue Reading
The overall response rate (ORR) was 7% in the treatment population, but MET-driven patients had a significantly higher response rate of 18% partial response vs MET-independent PRCC (0%).
Patients with MET-driven PRCC had a median progression-free survival (mPFS) of 6.2 months (95% CI: 4.1-7.0) vs 1.4 months in MET-independent PRCC (95% CI: 1.4-2.7), (hazard ratio [HR], 0.33; 95% CI: 0.20-0.52; log-rank P < .001).
RELATED: Restoring ASPP1 May Improve Outcomes in Clear Cell RCC
The most frequently observed adverse effects in patients were nausea, vomiting, fatigue, and peripheral edema.
Study authors concluded that “these results confirm that savolitinib, a potent and selective small-molecule MET kinase inhibitor, holds promise as a personalized treatment for patients with metastatic MET-driven PRCC.”
References
- Choueiri TK, Plimack E, Arkenau HT, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol. 2017 Jun 23. doi: 10.1200/JCO.2017.72.2967 [Epub ahead of print]
